Format

Send to

Choose Destination
See comment in PubMed Commons below
Shanghai Arch Psychiatry. 2016 Apr 25;28(2):64-71. doi: 10.11919/j.issn.1002-0829.216003.

Huperzine A for treatment of cognitive impairment in major depressive disorder: a systematic review of randomized controlled trials.

Author information

  • 1The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China.
  • 2China Clinical Research Center for Mental Disorders, Beijing, China, and Center of Depression, Beijing Institute for Brain Disorders, Beijing, China ; Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
  • 3School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Australia ; University of Notre Dame Australia / Marian Centre, Perth, Australia.
  • 4Department of Psychiatry, Chinese University of Hong Kong, Hong Kong SAR, China.
  • 5Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia.
  • 6Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China.
  • 7Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao SAR, China.

Abstract

in English, Chinese

BACKGROUND:

Acetylcholinesterase (AChE) inhibitors have been shown to be effective in treating cognitive impairment in animal models and in human subjects with major depressive disorder (MDD). Huperzine A (HupA), a Traditional Chinese Medicine derived from a genus of clubmosses known as Huperzineserrata, is a powerful AChE inhibitor that has been used as an adjunctive treatment for MDD, but no meta-analysis on HupA augmentation for MDD has yet been reported.

AIM:

Conduct a systematic review and meta-analysis of randomized controlled trials (RCTS) about HupA augmentation in the treatment of MDD to evaluate its efficacy and safety.

METHODS:

Two evaluators independently searched nine English-language and Chinese-language databases, selected relevant studies that met pre-determined inclusion criteria, extracted data about outcome and safety, and conducted quality assessments and data synthesis.

RESULTS:

Three low-quality RCTs (pooled n=238) from China were identified that compared monotherapy antidepressant treatment for depression versus combined treatment with antidepressants and HupA. Participants in the studies ranged from 16 to 60 years of age. The average duration of adjunctive antidepressant and HupA treatment in the studies was only 6.7 weeks. All three studies were open label and non-blinded, so their overall quality was judged as poor. Meta-analysis of the pooled sample found no significant difference in the improvement in depressive symptoms between the two groups (weighted mean difference: -1.90 (95%CI: -4.23, 0.44), p=0.11). However, the adjunctive HupA group did have significantly greater improvement than the antidepressant only group in cognitive functioning (as assessed by the Wisconsin Card Sorting Test and the Wechsler Memory Scale-Revised) and in quality of life. There was no significant difference in the incidence of adverse drug reactions between groups.

CONCLUSIONS:

The data available on the effectiveness and safety of adjunctive treatment using HupA in patients with MDD who are receiving antidepressants is insufficient to arrive at a definitive conclusion about its efficacy and safety. Pooling of the data from three low-quality RCTs from China found no advantage of adjunctive HupA in the treatment of depressive symptoms, but adjunctive treatment with HupA was associated with a faster resolution of the cognitive symptoms that frequently accompany MDD.

KEYWORDS:

adjunctive treatment; cognitive function; depression; huperzine A; meta-analysis

Publication Types

Publication Types

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center